儿童和青少年非霍奇金淋巴瘤的治疗结果及毒性模式：单机构经验
Outcome and Toxicity Patterns in Children and Adolescents with Non-Hodgkin Lymphoma: A Single Institution Experience.
作者信息
Angelini Paola, Rodriguez Laura, Zolaly Mohammed, Naqvi Ahmed, Weitzman Sheila, Abla Oussama, Punnett Angela
机构信息
Paediatric Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
出版信息
Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018020. doi: 10.4084/MJHID.2018.020. eCollection 2018.
BACKGROUND
The incidence and biology of non-Hodgkin lymphoma (NHL) vary according to age. Some data suggest that the impact of age in pediatric and adolescent NHL patients depends on the histological subtype. Objectives: We aimed to analyze the impact of age at diagnosis on clinical characteristics and treatment-related toxicity in children and adolescents with NHL.
METHODS
Retrospective review of medical records of children and adolescents diagnosed with NHL at the Hospital for Sick Children, Toronto, between January 1995 and December 2008.
RESULTS
164 children were diagnosed with NHL during the study period, with a median age at diagnosis of 10 years. With a median follow-up of 6.2 years, 5-year OS in patients aged <15 and 15-18 years was 89± 2% 82% ± 6%, respectively ( = 0.30), and 5-year EFS was 84% ± 3% 77% ± 7% (= 0.37). In Burkitt's lymphoma (BL) and lymphoblastic lymphoma (LL) there was a trend towards better outcomes in children compared to adolescents, with EFS of 91% ± 4% 75% ± 15%, respectively in BL (= 0.17), and 82% ± 7% 51.4% ± 2% respectively in LL (= 0.16). Late effects occurred in 21 patients (12.8%).
CONCLUSIONS
Children with NHL aged < 15 years tend to have better survival rates and similar long-term toxicity than adolescents aged 15-18 years.
背景
非霍奇金淋巴瘤（NHL）的发病率和生物学特性随年龄而异。一些数据表明，年龄对儿童和青少年NHL患者的影响取决于组织学亚型。目的：我们旨在分析诊断时的年龄对儿童和青少年NHL患者临床特征及治疗相关毒性的影响。
方法
回顾性分析1995年1月至2008年12月期间在多伦多病童医院被诊断为NHL的儿童和青少年的病历。
结果：在研究期间，164名儿童被诊断为NHL，诊断时的中位年龄为10岁。中位随访6.2年，年龄<15岁和15 - 18岁患者的5年总生存率分别为89±2%和82%±6%（P = 0.30），5年无事件生存率分别为84%±3%和77%±7%（P = 0.37）。在伯基特淋巴瘤（BL）和淋巴母细胞淋巴瘤（LL）中，儿童的预后趋势优于青少年，BL的无事件生存率分别为91%±4%和75%±15%（P = 0.17），LL分别为82%±7%和51.4%±2%（P = 0.16）。21名患者（12.8%）出现晚期效应。
结论
年龄<15岁的NHL儿童比15 - 18岁的青少年往往有更好的生存率和相似的长期毒性。
Zotero 插件